Dudediligence.

Contineum Therapeutics, Inc

CTNMNASDAQ · Pharmaceutical Preparations
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$2,161,756

19 notices · 146,036 sh

Oct 2025 to Oct 2026

Reported ·

$1,858,437

31 sales · 0 buys

Oct 2025 to Sep 2026

The two figures cover different periods.

All 31 reported sales carry the 10b5-1 box. Together they are 0.53% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Sep 2026N2025DJ2026FMAMJJASO2026-10-01: Daniel Lorrain, Form 1442026-09-08: CARMINE STENGONE, Form 1442026-09-01: Daniel Lorrain, Form 1442026-08-03: CARMINE STENGONE, Form 1442026-08-03: Daniel Lorrain, Form 1442026-07-08: CARMINE STENGONE, Form 1442026-07-01: Daniel Lorrain, Form 1442026-06-30: Daniel Lorrain, Form 1442026-06-30: CARMINE STENGONE, Form 1442026-06-30: TIMOTHY WATKINS, Form 1442026-06-01: DANIEL LORRAIN, Form 1442026-05-01: DANIEL LORRAIN, Form 1442026-04-06: DANIEL LORRAIN, Form 1442026-02-11: DANIEL LORRAIN, Form 1442026-02-11: CARMINE STENGONE, Form 1442026-02-03: DANIEL LORRAIN, Form 1442026-01-05: DANIEL LORRAIN, Form 1442025-12-29: TIMOTHY WATKINS, Form 1442025-12-23: DANIEL LORRAIN, Form 1442025-12-23: Lorrain Daniel S., sold2025-12-29: Watkins Tim, sold2026-01-05: Lorrain Daniel S., sold2026-01-28: Watkins Tim, sold2026-02-03: Lorrain Daniel S., sold2026-02-11: Lorrain Daniel S., sold2026-02-11: Stengone Carmine N., sold2026-02-19: Lorrain Daniel S., sold2026-02-24: Lorrain Daniel S., sold2026-02-24: Stengone Carmine N., sold2026-03-02: Watkins Tim, sold2026-03-02: Lorrain Daniel S., sold2026-04-06: Lorrain Daniel S., sold2026-05-01: Lorrain Daniel S., sold2026-06-01: Lorrain Daniel S., sold2026-06-30: Stengone Carmine N., sold2026-06-30: Watkins Tim, sold2026-06-30: Lorrain Daniel S., sold2026-07-08: Stengone Carmine N., sold2026-07-08: Lorrain Daniel S., sold2026-08-03: Stengone Carmine N., sold2026-09-08: Stengone Carmine N., sold
under a ▼ salesize is dollars

Form 144 notices, newest first

2026-10-01Daniel Lorrain, Chief Scientific Officer$55,961
4,170 shplan 2025-09-23Form 4s on file end Sep 23144 ↗
2026-09-08CARMINE STENGONE, CEO and President$41,750
2,500 shplan 2025-09-23144 ↗
Form 4, 2026-09-08: sold 2,500 at $16.46 Form 4 ↗
2026-09-01Daniel Lorrain, Chief Scientific Officer$154,605
9,520 shplan 2025-09-23Form 4s on file end Sep 23144 ↗
2026-08-03CARMINE STENGONE, CEO and President$38,725
2,500 shplan 2025-09-23144 ↗
Form 4, 2026-08-03: sold 2,500 at $16.01 Form 4 ↗
2026-08-03Daniel Lorrain, Chief Scientific Officer$147,465
9,520 shplan 2025-09-23Form 4s on file end Sep 23144 ↗
2026-07-08CARMINE STENGONE, CEO and President$36,400
2,500 shplan 2025-09-23144 ↗
Form 4, 2026-07-08: sold 2,500 at $16.00 Form 4 ↗
2026-07-01Daniel Lorrain, Chief Scientific Officer$156,033
9,520 shplan 2025-09-23144 ↗
Form 4, 2026-07-10: sold 1,040 at $16.00 Form 4 ↗
2026-06-30Daniel Lorrain, Chief Scientific Officer$432,390
28,826 shplan 2025-09-23144 ↗
Form 4, 2026-07-02: sold 37,179 at $16.00 Form 4 ↗
2026-06-30CARMINE STENGONE, CEO and President$150,000
10,000 shplan 2025-09-23144 ↗
Form 4, 2026-07-01: sold 10,000 at $16.01 Form 4 ↗
2026-06-30TIMOTHY WATKINS, CMO & Head of Development$162,495
10,833 shplan 2025-09-23144 ↗
Form 4, 2026-07-01: sold 10,833 at $16.02 Form 4 ↗
2026-06-01DANIEL LORRAIN, Chief Scientific Officer$56,253
4,170 shplan 2025-09-23144 ↗
Form 4, 2026-06-01: sold 4,170 at $13.16 Form 4 ↗
2026-05-01DANIEL LORRAIN, Chief Scientific Officer$53,459
4,170 shplan 2025-09-23144 ↗
Form 4, 2026-05-01: sold 4,170 at $13.12 Form 4 ↗
2026-04-06DANIEL LORRAIN, Chief Scientific Officer$12,284
914 shplan 2025-09-23no Form 4 on file144 ↗
2026-02-11DANIEL LORRAIN, Chief Scientific Officer$252,788
16,050 shplan 2025-09-23144 ↗
Form 4, 2026-02-13: sold 400 at $16.00 Form 4 ↗
2026-02-11CARMINE STENGONE, CEO and President$118,125
7,500 shplan 2025-09-23144 ↗
Form 4, 2026-02-13: sold 400 at $16.00 Form 4 ↗
2026-02-03DANIEL LORRAIN, Chief Scientific Officer$59,965
4,170 shplan 2025-09-23144 ↗
Form 4, 2026-02-05: sold 4,170 at $14.94 Form 4 ↗
2026-01-05DANIEL LORRAIN, Chief Scientific Officer$47,496
4,170 shplan 2025-09-23144 ↗
Form 4, 2026-01-06: sold 4,170 at $10.44 Form 4 ↗
2025-12-29TIMOTHY WATKINS, CMO & Head of Development$134,438
10,833 shplan 2025-09-23144 ↗
Form 4, 2025-12-30: sold 3,611 at $12.06 Form 4 ↗
2025-12-23DANIEL LORRAIN, Chief Scientific Officer$51,124
4,170 shplan 2025-09-23144 ↗
Form 4, 2025-12-30: sold 4,170 at $12.23 Form 4 ↗